rs28931574
Variant summary
Our verdict is Pathogenic. Variant got 14 ACMG points: 14P and 0B. PM2PP3_StrongPP5_Very_Strong
The NM_000039.3(APOA1):c.148G>C(p.Gly50Arg) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★).
Frequency
Consequence
NM_000039.3 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 14 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
APOA1 | NM_000039.3 | c.148G>C | p.Gly50Arg | missense_variant | Exon 3 of 4 | ENST00000236850.5 | NP_000030.1 |
Ensembl
Frequencies
GnomAD3 genomes Cov.: 33
GnomAD4 exome Cov.: 35
GnomAD4 genome Cov.: 33
ClinVar
Submissions by phenotype
Familial amyloid polyneuropathy, Iowa type Pathogenic:1
- -
not provided Pathogenic:1
This missense change has been observed in individual(s) with autosomal dominant systemic amyloidosis (PMID: 2123470). It has also been observed to segregate with disease in related individuals. This sequence change replaces glycine, which is neutral and non-polar, with arginine, which is basic and polar, at codon 50 of the APOA1 protein (p.Gly50Arg). This variant is not present in population databases (gnomAD no frequency). This variant is also known as glycine to arginine-26 substitution, ApoA-I Iowa, or G26R. ClinVar contains an entry for this variant (Variation ID: 17917). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt APOA1 protein function. Experimental studies have shown that this missense change affects APOA1 function (PMID: 17665932, 21296086, 22952757, 23233678, 27464946). For these reasons, this variant has been classified as Pathogenic. -
Familial amyloid polyneuropathy, Iowa type;C5551172:Hypoalphalipoproteinemia, primary, 2;C5677030:Hypoalphalipoproteinemia, primary, 2, intermediate Pathogenic:1
- -
Familial visceral amyloidosis, Ostertag type Pathogenic:1
This sequence change in APOA1 is predicted to replace glycine with arginine at codon 50, p.(Gly50Arg). Note, this variant is also referred to in the literature as p.(Gly26Arg). This glycine residue is critical for β-structure termination (PMID: 17665932, 27464946) and is highly conserved (100 vertebrate, Multiz Alignment). There is a large physicochemical difference between glycine and arginine. This variant is absent from the population database gnomAD v4.1. This variant has been reported in several probands with apolipoprotein-A1 familial amyloid polyneuropathy, including in one large multi-generational kindred in which the variant segregates with disease in the affected family members (PMID: 33502644, 2123470, 3142462, 4304452). Functional studies suggest this variant leads to decreased lipid binding function and promotion of amyloid formation (PMID: 17665932, 21296086, 23233678). Computational evidence predicts a deleterious effect for the missense substitution (REVEL = 0.7). Based on the classification scheme RMH Modified ACMG/AMP Guidelines v1.7.1, this variant is classified as PATHOGENIC. Following criteria are met: PM1, PM2_Supporting, PP1_Moderate, PP3, PS3_Supporting, PS4. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at